182 related articles for article (PubMed ID: 19802584)
1. Targeted mutagenesis as a rational approach to dengue virus vaccine development.
Blaney JE; Durbin AP; Murphy BR; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():145-58. PubMed ID: 19802584
[TBL] [Abstract][Full Text] [Related]
2. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Hanley KA; Manlucu LR; Manipon GG; Hanson CT; Whitehead SS; Murphy BR; Blaney JE
Vaccine; 2004 Sep; 22(25-26):3440-8. PubMed ID: 15308370
[TBL] [Abstract][Full Text] [Related]
3. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.
Wright PF; Durbin AP; Whitehead SS; Ikizler MR; Henderson S; Blaney JE; Thumar B; Ankrah S; Rock MT; McKinney BA; Murphy BR; Schmidt AC
Am J Trop Med Hyg; 2009 Nov; 81(5):834-41. PubMed ID: 19861619
[TBL] [Abstract][Full Text] [Related]
5. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
6. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
7. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.
Blaney JE; Johnson DH; Firestone CY; Hanson CT; Murphy BR; Whitehead SS
J Virol; 2001 Oct; 75(20):9731-40. PubMed ID: 11559806
[TBL] [Abstract][Full Text] [Related]
8. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
9. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
10. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
[TBL] [Abstract][Full Text] [Related]
11. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
Blaney JE; Sathe NS; Goddard L; Hanson CT; Romero TA; Hanley KA; Murphy BR; Whitehead SS
Vaccine; 2008 Feb; 26(6):817-28. PubMed ID: 18191005
[TBL] [Abstract][Full Text] [Related]
12. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
13. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
[TBL] [Abstract][Full Text] [Related]
14. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
Whitehead SS; Hanley KA; Blaney JE; Gilmore LE; Elkins WR; Murphy BR
Vaccine; 2003 Oct; 21(27-30):4307-16. PubMed ID: 14505913
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
McArthur JH; Durbin AP; Marron JA; Wanionek KA; Thumar B; Pierro DJ; Schmidt AC; Blaney JE; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2008 Nov; 79(5):678-84. PubMed ID: 18981503
[TBL] [Abstract][Full Text] [Related]
16. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
Durbin AP; McArthur JH; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
Hum Vaccin; 2006; 2(6):255-60. PubMed ID: 17106267
[TBL] [Abstract][Full Text] [Related]
17. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
[TBL] [Abstract][Full Text] [Related]
18. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
19. Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2.
Stauft CB; Song Y; Gorbatsevych O; Pantoja P; Rodriguez IV; Futcher B; Sariol CA; Wimmer E
Virology; 2019 Nov; 537():237-245. PubMed ID: 31539771
[TBL] [Abstract][Full Text] [Related]
20. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
